| Execution period | 12 months |
|---|
NSE filing, NSE: PURVA. Summary written from the filing by ALFA Finder's alert engine.
Puravankara Ltd: key numbers
- Share price
- ₹205.50
- Market cap
- ₹4,873 Cr
- Revenue (annual)
- ₹3,740 Cr
- Net profit (annual)
- ₹63.71 Cr
- P/E (TTM)
- 17.2×Sector 38.0×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 16.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Puravankara Ltd
All →Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.
Puravankara Earnings Call Transcript: Key Takeaways
Puravankara delivered record sales growth and debt reduction, though margins face short-term pressure from front-loaded marketing and approval costs.
Puravankara Results Update
Puravankara's Q2FY27 revenue rose 59% to ₹1,051 crore and PAT reached ₹82 crore. The press release also covers sales, handovers and new land and project additions.
Puravankara Investor Presentation: Key Takeaways
Q2 FY27 total income ₹1,051 Cr (+59% YoY), PAT ₹82 Cr vs ₹-42 Cr loss; Q2 sales value ₹2,136 Cr (+62%). Pivot to redevelopment and Delhi-NCR expansion.
Puravankara Q2 FY27 Results: Turns Profitable, Net Profit ₹83.7 Cr
Puravankara Ltd reported revenue from operations of ₹1,032 Cr (+60.3% YoY) and net profit of ₹83.7 Cr for Q2 FY27.
- Key figure
- Net profit ₹83.7 Cr
Puravankara Board Meeting Date
Puravankara will hold a board meeting on 2 November 2026 to consider unaudited quarter and half-year results. The trading window stays closed until 4 November 2026.
Other board meeting outcome announcements
All →Ennature Bio Pharma Board Meeting Outcome
Ennature Bio Pharma's board approved adoption of new Articles of Association to align with SCRA Rules 1957 and group governance. The change is subject to shareholder approval.
Shri Keshav Cements & Infra Board Meeting Outcome
Shri Keshav Cements' board approved un-audited financial and segment-wise revenue results for the quarter and half-year ended 30 September 2026. No other material decisions were transacted.
Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.